Comparing the differential effects of LPA on the barrier function of human pulmonary endothelial cells

Comparing the differential effects of LPA on the barrier function of human pulmonary endothelial cellsGPCR Target: LPA2/LPA5Authors: Yonglin Ren, et al.Company: Hoffmann-La Roche Inc.Journal: Microvascular Research Volume 85, January 2013,…

Continue ReadingComparing the differential effects of LPA on the barrier function of human pulmonary endothelial cells

Big conductance calcium‐activated potassium channel openers control spasticity without sedation

Big conductance calcium‐activated potassium channel openers control spasticity without sedationGPCR Target: GPR55Authors: David Baker, et al.Company: Queen Mary University of LondonJournal: British Pharmacology JournalsYear Published: 2017

Continue ReadingBig conductance calcium‐activated potassium channel openers control spasticity without sedation

Dual MET and SMO Negative Modulators Overcome Resistance to EGFR Inhibitors in Human Nonsmall Cell Lung Cancer

Dual MET and SMO Negative Modulators Overcome Resistance to EGFR Inhibitors in Human Nonsmall Cell Lung CancerGPCR Target: SMOAuthors: Floriana Morgillo, et al.Company: Università della Campania “Luigi Vanvitelli” / Universitàdi…

Continue ReadingDual MET and SMO Negative Modulators Overcome Resistance to EGFR Inhibitors in Human Nonsmall Cell Lung Cancer

Synthesis and pharmaceutical characterization of site specific mycophenolic acid-modified Xenopus glucagon-like peptide-1 analogs

Synthesis and pharmaceutical characterization of site specific mycophenolic acid-modified Xenopus glucagon-like peptide-1 analogsGPCR Target: GLP-1Authors: Jing Han, et al.Company: Jiangsu Normal University / Nanjing Medical University / Jiaxing UniversityJournal: Royal…

Continue ReadingSynthesis and pharmaceutical characterization of site specific mycophenolic acid-modified Xenopus glucagon-like peptide-1 analogs

Pharmacology of Parsabiv® (etelcalcetide, ONO-5163/AMG 416), a novel allosteric modulator of the calcium-sensing receptor, for secondary hyperparathyroidism in hemodialysis patients

Pharmacology of Parsabiv® (etelcalcetide, ONO-5163/AMG 416), a novel allosteric modulator of the calcium-sensing receptor, for secondary hyperparathyroidism in hemodialysis patientsGPCR Target: Ca-sensingAuthors: Kazutsune Harada, et al.Company: Ono Pharmaceutical Co.Journal: European…

Continue ReadingPharmacology of Parsabiv® (etelcalcetide, ONO-5163/AMG 416), a novel allosteric modulator of the calcium-sensing receptor, for secondary hyperparathyroidism in hemodialysis patients

Loss of Free Fatty Acid Receptor 2 leads to impaired islet mass and beta cell survival

Loss of Free Fatty Acid Receptor 2 leads to impaired islet mass and beta cell survivalGPCR Target: FFA2Authors: Stephanie R. Villa, et al.Company: Northwestern University Feinberg School of Medicine /…

Continue ReadingLoss of Free Fatty Acid Receptor 2 leads to impaired islet mass and beta cell survival

Homology modeling of FFA2 identifies novel agonists that potentiate insulin secretion.

Homology modeling of FFA2 identifies novel agonists that potentiate insulin secretion.GPCR Target: Free Fatty AcidAuthors: Villa SR, et al.Company: Northwestern University / University of Illinois at Chicago / Midwestern University…

Continue ReadingHomology modeling of FFA2 identifies novel agonists that potentiate insulin secretion.

Effects of LTB4 receptor antagonism on pulmonary inflammation in rodents and non-human primates.

Effects of LTB4 receptor antagonism on pulmonary inflammation in rodents and non-human primates.GPCR Target: BLT1/BLT2Authors: Hicks A, et al.Company: RocheJournal: Prostaglandins Other Lipid Mediat. June 2010; 92(1-4):33-43Year Published: 2010

Continue ReadingEffects of LTB4 receptor antagonism on pulmonary inflammation in rodents and non-human primates.

Development of a FLIPR assay for the simultaneous identification of MrgD agonists and antagonists from a single screen.

Development of a FLIPR assay for the simultaneous identification of MrgD agonists and antagonists from a single screen.GPCR Target: MrgX1Authors: Ajit SK, et al.Company: Drexel University College of Medicine /…

Continue ReadingDevelopment of a FLIPR assay for the simultaneous identification of MrgD agonists and antagonists from a single screen.

Critical Cysteine Residues in Both the Calcium-Sensing Receptor and the Allosteric Activator AMG 416 Underlie the Mechanism of Action.

Critical Cysteine Residues in Both the Calcium-Sensing Receptor and the Allosteric Activator AMG 416 Underlie the Mechanism of Action.GPCR Target: CaSRAuthors: Alexander ST, et al.Company: AmgenJournal: Mol Pharmacol. November 2015;…

Continue ReadingCritical Cysteine Residues in Both the Calcium-Sensing Receptor and the Allosteric Activator AMG 416 Underlie the Mechanism of Action.